Background: Comprehensive capture of Adverse Events (AEs) is crucial for monitoring for side effects of a therapy while assessing efficacy. For cancer studies, the National Cancer Institute has developed the Common Terminology Criteria for Adverse Events (CTCAE) as a required standard for recording attributes and grading AEs. The AE assessments should be part of the Electronic Health Record (EHR) system; yet, due to patient-centric EHR design and implementation, many EHR’s don’t provide straightforward functions to assess ongoing AEs to indicate a resolution or a grade change for clinical trials. Methods: At UAMS, we have implemented a standards-based Adverse Event Reporting System (AERS) that is integrated with the Epic EHR and other resea...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
The identification and grading of adverse events (AEs) during the conduct of clinical trials is a la...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...
PURPOSE: To report meetings of the Applied Radiation Biology and Radiotherapy section of the Interna...
Purpose—To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter cli...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
The occurrence of adverse events frequently accompanies tumor treatments. Side effects should be det...
PURPOSE: Adverse event (AE) reporting is essential in clinical trials. Clinician interpretation can...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
Studies indicate that voluntary reporting detects relatively few adverse events (AEs) (Ehland et al....
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
The identification and grading of adverse events (AEs) during the conduct of clinical trials is a la...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...
PURPOSE: To report meetings of the Applied Radiation Biology and Radiotherapy section of the Interna...
Purpose—To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter cli...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
The occurrence of adverse events frequently accompanies tumor treatments. Side effects should be det...
PURPOSE: Adverse event (AE) reporting is essential in clinical trials. Clinician interpretation can...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
Studies indicate that voluntary reporting detects relatively few adverse events (AEs) (Ehland et al....
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
The identification and grading of adverse events (AEs) during the conduct of clinical trials is a la...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...